Evidence map›Paper›PMID 37643638›Full record

ArticleJNCI cancer spectrum2023

In-office dispensing of oral targeted agents by urology practices in men with advanced prostate cancer.

Dawson Hill, Samuel R Kaufman, Mary K Oerline, Kassem Faraj, Megan E V Caram, Vahakn B Shahinian, Brent K Hollenbeck, Avinash Maganty

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JNCI cancer spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Dawson HillDow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Samuel R KaufmanDow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Mary K OerlineDow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Kassem FarajDow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Megan E V CaramDivision of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Vahakn B ShahinianDow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Brent K HollenbeckDow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Avinash MagantyDow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-6436-6667
University of Michigan · US

Funding

Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patientsR01CA275993 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOLLENBECK, BRENT K., SHAHINIAN, VAHAKN B · 2023 to 2025
$2.5M
Impact of urologist practice organization and health policy on prostate cancer treatment, overtreatment and spendingR01HS025707 · AHRQ · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOLLENBECK, BRENT K., SHAHINIAN, VAHAKN B · 2017 to 2021
$1.7M
Impact of the Merit-Based Incentive Payment System on the Quality of Prostate Cancer CareF32CA275021 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MAGANTY, AVINASH · 2022 to 2022
$86k
AHRQ HHS R01 HS025707NCI NIH HHS F32 CA275021NCI NIH HHS R01 CA275993
6 · The paper itself

Abstract

backgroundManagement of men with advanced prostate cancer has evolved to include urologists, made possible by oral targeted agents (eg, abiraterone or enzalutamide) that can be dispensed directly to patients in the office. We sought to investigate whether this increasingly common model improves access to these agents, especially for Black men who are historically undertreated.

methodsWe used 20% national Medicare data to perform a retrospective cohort study of men with advanced prostate cancer from 2011 through 2019, managed by urology practices with and without in-office dispensing. Using a difference-in-difference framework, generalized estimating equations were used to measure the effect of in-office dispensing on prescriptions for abiraterone and/or enzalutamide, adjusting for differences between patients, including race.

resultsNew prescription fills for oral targeted agents increased after the adoption of in-office dispensing (+4.4%, 95% confidence interval [CI] = 3.4% to 5.4%) relative to that for men managed by practices without dispensing (+2.4%, 95% CI = 1.4% to 3.4%). The increase in the postintervention period (difference-in-difference estimate) was 2% higher (95% CI = 0.6% to 3.4%) for men managed by practices adopting dispensing relative to men managed by practices without dispensing. The effect was strongest for practices adopting dispensing in 2015 (difference-in-difference estimate: +4.2%, 95% CI = 2.3% to 6.2%). The effect of dispensing adoption did not differ by race.

conclusionAdoption of in-office dispensing by urology practices increased prescription fills for oral targeted agents in men with advanced prostate cancer. This model of delivery may improve access to this important class of medications.

Indexed as

Antineoplastic AgentsProstatic NeoplasmsUrologyAgedBenzamidesHumansMaleMedicareNitrilesPhenylthiohydantoinRetrospective StudiesUnited StatesAntineoplastic AgentsBenzamidesenzalutamideNitrilesPhenylthiohydantoin

Identifiers

PMID37643638
PMCPMC10555918
OpenAlexW4386242064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.